The voglibose market was valued at USD3,549.3Mn by 2019. As per the research citings provided by the World Health Organization (WHO), it is estimated that more than 422 million people throughout the globe are suffering from type 2 diabetes mellitus. Increasing public health awareness pertaining to diabetes has resulted in the early detection of postprandial hyperglycemia which further propels the voglibose market.

Voglibose is categorized as an α glucosidase inhibitors, it was discovered in Japan in 1981 when it was isolated from the culture media producing Streptomyces hygroscopicity var. limonons and was commercially available since 1995 for the treatment of postprandial hyperglycemia. It exerts an anti-hypoglycemic action from a reversible inhibition of the membrane-bound intestinal enzyme α glycosidase hydrolyze and prevents the increase in blood glucose level post-meal.

The major segments related to the voglibose market are:

By Clinical Application (2017–2027; US$ Mn)

Postprandial Hyperglycemia

Type 1b Glycogen Storage Disease

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global voglibose market
• The overall segmentation of the voglibose market, by clinical application, distribution channel, and geography is minutely studied. Postprandial hyperglycemia and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
• Significant rise in the non-insulin dependent diabetes patients worldwide primarily drive the voglibose market growth
• A growing inclination for junk food consumption and unhealthy lifestyle further propels the voglibose market growth

Report gist?

• The study of the global voglibose market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in the manufacturing and marketing of voglibose owing to its popularity as a prescribed drug for non-insulin dependent diabetes patients
• The report will benefit diabetologist engaged in prescribing medicines to type 2 diabetes patients
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to voglibose market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Postprandial hyperglycemia is defined by the plasma glucose level exceeding 140mg/dl, it usually occurs when there is some kind of impairment of the first phase of insulin response which causes a reduced insulin sensitivity in the peripheral tissues with lower suppression of hepatic glucose post meals. A significant rise in physical inactivity and an unhealthy lifestyle together drive the demand for voglibose in the treatment of postprandial hyperglycemia. Type 1b glycogen storage disease is a rare disease that usually occurs in 1 per 100,000 births throughout the globe. Voglibose has been extensively studied in the clinical trials for its therapeutic efficacy and safety for the treatment of type 1b glycogen storage disease.

Hospital pharmacy is presently dominating the distribution channel segment for the voglibose market. The chief contributing factor responsible for its impressive market growth is the rising public health awareness resulting in a large number of patients visiting hospital pharmacy with prescription of voglibose for the treatment of type 2 diabetes mellitus. Retail pharmacy is expected to register magnificent market growth during the forecast period owing to the exponential growth in the generic drug market worldwide and the capability to serve pre-diabetic patients in remote locations.

North America is holding the largest market share in the voglibose market. The rising prevalence of type 2 diabetes primarily determines the overwhelming market performance for voglibose in the regional segment. As per the latest statistics brought forward by the Center for Disease Control and Prevention, (CDC), approximately 34 million Americans are suffering from type 2 diabetes. Affordable reimbursement scenario provided for the use of voglibose in the treatment of postprandial hyperglycemia further consolidates the voglibose market growth in the region. Europe is in the 2nd position in the regional segment for the voglibose market. As per the latest report presented by the European Commission, the type 1b glycogen storage disease occurs in 1 in 20,000 Ashkenazi Jews population inhabiting the Eastern European region. The supportive regulatory environment provided by the European Medical Agency (EMA) for the sale and distribution of voglibose further propels the market growth in the region. Asia Pacific is keen to showcase rampant market growth in the near future on account of a significant rise in obesity, sedentary lifestyle, consumption of junk food causing the early occurrence of type 2 diabetes in the young population in the region.